Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Basilea Pharmaceutica AG (OTC: BPMUF).

Full DD Report for BPMUF

You must become a subscriber to view this report.


Recent News from (OTC: BPMUF)

Basilea Pharmaceutica AG 2018 Q2 - Results - Earnings Call Slides
The following slide deck was published by Basilea Pharmaceutica AG in conjunction with their 2018 Q2 earnings Read more ...
Source: SeekingAlpha
Date: August, 15 2018 13:38
Basilea Pharmaceutica AG (BPMUF) CEO David Veitch on Q2 2018 Results - Earnings Call Transcript
Basilea Pharmaceutica AG (BPMUF) Q2 2018 Results Earnings Conference Call August 14, 2018 10:00 AM ET Executives David Veitch - Chief Executive Officer Adesh Kaul - Chief Corporate Development Officer Marc Engelhardt - Chief Medical Officer Donato Spota - Chief Financial Office...
Source: SeekingAlpha
Date: August, 14 2018 15:37
Basilea Pharmaceutica (BPMUF) Presents At Biotech Days, Kepler Cheuvreux - Slideshow
The following slide deck was published by Basilea Pharmaceutica AG in conjunction with this Read more ...
Source: SeekingAlpha
Date: June, 22 2018 12:00
Mining ASCO 2018's Gold, Part 5: There's A Lot To Look Forward To
The 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO 2018) is upon us, and it's about as close to Christmas as I get in my line of work. There's so much data presented here, with thousands of abstracts delivered to an audience of some 30,000 healthcare professionals, that...
Source: SeekingAlpha
Date: May, 27 2018 09:00
Basilea Pharmaceutica's (BPMUF) CEO Ronald Scott on Full Year 2017 Results - Earnings Call Transcript
Basilea Pharmaceutica AG (BPMUF) Full Year 2017 Earnings Conference Call February 27, 2018 10:00 A.M. ET Executives Ronald Scott - Chief Executive Officer Marc Engelhardt - Chief Medical Officer David Veitch - Chief Commercial Officer and Chief Executive Officer-designate Donat...
Source: SeekingAlpha
Date: March, 01 2018 01:14
Basilea Pharmaceutica AG reports FY results
Basilea Pharmaceutica AG ( OTC:BPMUF ): FY EPS of -CHF1.79 More news on: Basilea Pharmaceutica AG, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: February, 27 2018 01:29
Week In Review: China Life Science Deals Total $550 Million
Deals and Financings Pfizer (NYSE: [[PFE]]) signed a $226 million agreement for China/Asian rights to Cresemba (isavuconazole), an antifungal drug developed by Swiss pharma Basilea (BPMUF). Previously, Pfizer acquired rights for Cresemba in Europe, Russia, Turkey and Israel. In the latest ...
Source: SeekingAlpha
Date: December, 10 2017 07:46
Basilea Pharmaceutica (BPMUF) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
The following slide deck was published by Basilea Pharmaceutica AG in conjunction with this Read more ...
Source: SeekingAlpha
Date: November, 16 2017 13:37
Week In Review: Another Billion Dollar Week For China Life Science Deals
Deals and Financings Shanghai Pharma Holding (SHA: 601607) may acquire part of Alvogen - possibly Alvogen's US operations - according to Bloomberg. Alvogen is a US-based generic drug maker thought to be worth as much as $4 billion. It has operations in Asia, including China, along with e...
Source: SeekingAlpha
Date: October, 01 2017 07:55

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-17N/A43.30N/AN/A0
2018-12-1443.3043.3043.3043.3025
2018-12-13N/A45.175N/AN/A0
2018-12-12N/A45.175N/AN/A0
2018-12-11N/A45.175N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-10-0420023385.8369Short
2018-09-1810012083.3333Short
2018-09-173838100.0000Short
2018-08-22250250100.0000Short
2018-08-13250250100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BPMUF.


About Basilea Pharmaceutica AG (OTC: BPMUF)

Logo for Basilea Pharmaceutica AG (OTC: BPMUF)

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland. The company focuses on providing innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology, targeting the medical challenge of rising resistance and non response to current treatment options.

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $665,569,109 - 03/16/2018
  • Issue and Outstanding: 9,587,570 - 10/21/2011

 



Daily Technical Chart for (OTC: BPMUF)

Daily Technical Chart for (OTC: BPMUF)


Stay tuned for daily updates and more on (OTC: BPMUF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BPMUF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BPMUF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BPMUF and does not buy, sell, or trade any shares of BPMUF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/